“Evidencias en Pediatría” (Evidences in Pediatrics) is a journal published only for health professionals. If you are not a health professional and you are visiting this site, you should know that the provided information can never replace the relationship between you and your doctor.
Privacy and data protection
The editorial board of the journal Evidencias en Pediatría (EP) takes very seriously the privacy of users’ data. Under no circumstances does it redistribute, sell, or make any kind of transfer of information obtained from visitors.
In accordance with the current legislation, if you have voluntarily submitted information to our site, you can use your right to modify it or cancel it by contacting the technical team of this website. Under the current legislation, the information form file, called “electronic table of contents” (e-TOC) has been declared to the Agencia de Protección de Datos (Spanish Agency for Data Protection) https://www.agpd.es/portalwebAGPD/index-ides-idphp.php
Links to external sites
This page may include links to other websites that might be of interest to users. This does not involve any property or responsibility of this journal site on the content of such links, neither on the updating or access conditions. However, these items are checked regularly by the Evidencias en Pediatría (EP) journal Editorial Board.
Linking from external sites
Linking to this website is permitted, and we promote and encourage it. There is no need of previous approval of any kind to link us. In all cases, the links should lead to a full display of the journal Evidencias en Pediatría website and never in other sites’ frames. The complete web address of the journal Evidencias en Pediatría (EP) has to appear always in the address toolbar. This could be a problem when linking to us from websites that use frames. In case that you have technical problems to achieve this, even when you are trying to link us out of any frame, please contact us.
Free Software mentioned in the site
The journal Evidencias en Pediatría (EP / Evidences in Pediatrics) includes occasional references to some kind of free software. Included links lead directly to the companies and organizations websites where this material is offered. The visitor accessing these links should carefully follow the instructions provided for each company to access their software. The journal EP Editorial Board is beyond any possible relationships generated between visitors and those entities. For any question please send an email using the mail form that we offer.
Rights of the author, editor and reader
The journal Evidencias en Pediatría does not demand from the authors the donation of their right on their manuscripts as a requisite to publish them. The relationship between the magazine and the authors will be regulated as it is described below.
The journal Evidencias en Pediatría (Evidences in Pediatrics) recognizes as inalienable the intellectual and moral rights of the authors concerning the content of their published manuscripts. Any use of these manuscripts must recognize this authorship in an explicit manner.
The journal Evidencias en Pediatría (EP / Evidences in Pediatrics) therefore, accepts that the authors could deposit, at institutional repositories or personal websites, an electronic copy of the revised and finally accepted version of the manuscript once it has been already published. This deposit will be done under the responsibility of the authors and specifically mention the original source (website of the journal Evidencías en Pediatría) where the original version can be found.
The property and rights of the published manuscripts, in its final format, are reserved to and are shared by the journal Evidencias en Pediatría (Evidences in Pediatrics) and the authors. The management of the manuscripts is left to the publisher as an exclusive competence.
However, as one of the goals of Evidencias en Pediatría (EP / Evidences in Pediatrics) is the maximum spread and circulation of its articles among the scientific and professional community, it is permitted to download (from the website: www.evidenciasenpediatria.es) and file a copy of them for individual and private use and without any financial gain. Any use outside these limits must have prior permission of the publisher. In some cases the copy and use may be abide by payment of economic rights that the publisher will manage in common with the authors, according to the publisher standards. In this case it could be formalized as a publishing rights management contract.
The publishing policy in relation to Evidencias en Pediatría web users (www.evidenciasenpediatria.es) assumes the terms of a Creative Commons ® license of Attribution-Non Commercial - No Derivative Works kind. (http://creativecommons.org/licenses/by-nc-nd/3.0/en/).
Evidencias en Pediatría (EP / Evidences in Pediatrics) is a publication of the “Asociación Española de Pediatría” (AEP / Spanish Association of Pediatrics). Its contents are elaborated mainly by members of the Grupo de Trabajo de Pediatría Basada en la Evidencia (Evidence Based Pediatrics Working Group). This group is part of both, the AEP and the “Asociación Española de Pediatría de Atención Primaria” (Spanish Association of Primary Care Pediatrics / AEPap).
Orejón de Luna G, Fernández Rodríguez M. Tacrolimus, ¿qué lugar ocupa en el tratamiento de la dermatitis atópica? Evid Pediatr. 2015;11:2.
Bieber T, Vick K, Fölster-Holst R, Belloni-Fortina A, Städtler G, Worm M, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62:184.
Doss N, Kamoun MR, Dubertret L, Cambazard F,Remitz A, Lahfa M, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate to severe atopic dermatitis: evidence from a randomized, double-blind non inferiority trial vs fluticasone 0.005% ointment. Pediatr Allergy Immunol. 2010;21:321.
Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109:539-46.
Reitamo JH, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, Smith C, et al. 0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150:554-62.
Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010;21:144-56.
Svensson A, Chambers C, Gånemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin. 2011;27:1395-406.
Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, HunterJJ, et al. The UK working party’s diagnostic criteria for atopicdermatitis. Br J Dermatolol. 1994;131:383-96.
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eccema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10:11-8.
Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat. 2010; 21:34-44.
Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL, et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics 2008;122:e1210-8.
Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, Gold MH, Kirsner RS, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3 times weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008; 58:990-9.
Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother. 2009;43:1956-63.
Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14:163-78.
Premio MEDES 2012
Premio a la transparencia del SNS
Avalado por: Asociación Latinoamericana de Pediatría
Licencias Creative Commons
Estamos en: Cochrane Plus
Estamos en: Epistemonikos
Colaboramos con Pacientes Online
Una plataforma de: Lúa Ediciones 3.0
Adheridos a la iniciativa All Trials
The content in Evidencias en Pediatría is subject to Creative Commons Attribution Non Commercial No Derivatives 3.0 España